Arcturus Therapeutics initiated with a Buy at H.C. Wainwright. H.C. Wainwright analyst Ed Arce started Arcturus Therapeutics with a Buy rating and $15 price target. The company is well positioned to realize the potential of mRNA therapeutics, Arce tells investors in a research note. The analyst believes Arcturus may initiate the first ever trial of an mRNA therapeutic dosed chronically via IV injection and views its “broad” RNA platform as “highly competitive and differentiated.”
https://thefly.com/landingPageNews.php?id=2889055
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.